This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Free Reports

J&J Buy of Aragon Deals a Blow to Medivation

Medivation now has a formidable competitor for prostate cancer therapy.

Winners And Losers in CLL at ASCO '13
Winners And Losers in CLL at ASCO '13

06/10/13 - 07:00 AM EDT

Drugs from Gilead Sciences and Roche stood out at ASCO this year, while Infinity's drug lagged.

Aveo's Future Depends on Triple-Negative Breast Cancer

Aveo's next chance to resurrect its flailing cancer drug will come in 2014/2015 with breast cancer study data.

Page 1 of 1
< Previous
Next >
Top Rated Stocks Top Rated Funds Top Rated ETFs